BMRN at a glance
Biomarin Pharmaceutical Inc (BMRN, SEC CIK 1048477) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Biomarin Pharmaceutical Inc (BMRN) reported revenue of $3.2 billion (up 12.9% from FY2024) and net income of $348.9 million. Diluted EPS was $1.80.
- As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Biomarin Pharmaceutical Inc (BMRN) shares worth $4.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Friberg Gregory R on November 18, 2026 of 5,147 shares at $58.81 per share.
- In the last 90 days, BMRN insiders reported 0 open-market purchases ($0) and 2 open-market sales ($1.5M) on Form 4, a net sale of $1.5M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.2B
- +12.9% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$1.5M
- 13F holders
- 35 funds
- $4.6B · −2 vs prior quarter
- Latest 8-K
- Nov 2, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Acquisition integration risk: April 2026 Amicus and August 2026 Alesta acquisitions expanded operations and increased execution complexity
- Liquidity risk: $736.0 million cash versus $4.2 billion debt, including 2027 Notes maturing in May 2027
- Regulatory pricing risk: IRA Medicare negotiations, inflation rebates, and EU HTA regulation increase downward pricing pressure
- Trade risk: 100% tariffs on certain patented pharmaceuticals and ingredients beginning September 29, 2026
- Manufacturing risk: GALAFOLD and POMBILITI rely on single-source third-party manufacturers
Management Discussion & Analysis
- Quarterly revenue $1,024.6M, up $248.5M YoY from $776.1M
- Gross margin 80.0% vs 81.9% YoY, pressured by lower-margin product mix
- Best performer: GALAFOLD revenue $151.8M, worst: NAGLAZYME revenue $107.8M, down $14.2M YoY
- Cash and investments $736.0M, down $1,316.8M from December 31, 2025; operating cash flow $577.0M
- Near-term headwinds: inconsistent government orders, macroeconomic volatility, $70.0M BMN 450 upfront payment in fourth quarter, higher debt expense
AI summary of the BMRN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026 announced November 2, 2026
- Detailed financial results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.025B, up 32% YoY, led by Metabolic Conditions revenue up 44% to $744M
- GAAP net loss $123M versus $31M loss, reflecting Amicus-related amortization, interest expense and acquisition charges
Item 2.02: Results of Operations and Financial Condition
- Alesta acquisition expected to add approximately $283 million of pre-tax IPR&D expense in Q3 2026
- Q3 GAAP and Non-GAAP diluted EPS impact: approximately $1.50 unfavorable
Item 1.01: Entry into a Material Definitive Agreement
- License grants Ascendis worldwide rights to commercialize TransCon CNP, including Yuviwel, across all indications
- BioMarin receives royalties of 20% on U.S. sales and 18% on EU, Brazil and South Korea sales through May 2030
AI summaries of BMRN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BMRN
Don't miss the next BMRN filing
- Alerts as it files. A push when BMRN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BMRN, by share count.
- Ask anything. An AI agent that reads every BMRN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Friberg Gregory R | Sell | Nov 18, 2026 | 5,147 | $58.81 |
| Friberg Gregory R | F | Sep 30, 2026 | 4,086 | $60.00 |
| Plenge Robert M | A | Sep 10, 2026 | 6,140 | - |
| Davis George Eric | Sell | Sep 2, 2026 | 17,557 | $66.28 |
| Enyedy Mark J | A | Jun 2, 2026 | 7,490 | - |
| ANDERSON ELIZABETH M | A | Jun 2, 2026 | 7,490 | - |
| Dere Willard H | A | Jun 2, 2026 | 7,490 | - |
| Ho Maykin | A | Jun 2, 2026 | 7,490 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.9B | $3.2B |
| Operating Income | - | $484.2M | $409.5M |
| Net Income | $167.6M | $426.9M | $348.9M |
| Op. Margin | - | 17.0% | 12.7% |
| Net Margin | - | 15.0% | 10.8% |
| Balance Sheet | |||
| Total Assets | $6.8B | $7.0B | $7.6B |
| Equity | - | $5.7B | $6.1B |
| ROE | - | 7.5% | 5.7% |
| Per Share | |||
| EPS | $0.87 | $2.21 | $1.80 |
| Cash Flow | |||
| Operating CF | - | $572.8M | $828.0M |
| CapEx | $96.7M | $85.4M | $103.0M |
Source: XBRL data in Biomarin Pharmaceutical Inc (BMRN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BMRN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 35 | $4.58B |
| Q2 2026 | 37 | $4.75B |
| Q1 2026 | 35 | $4.81B |
| Q4 2025 | 33 | $4.77B |
| Q3 2025 | 33 | $4.57B |
| Q2 2025 | 34 | $5.07B |
| Q1 2025 | 32 | $4.36B |
| Q4 2024 | 27 | $3.60B |
- Citadel Advisors LLC+1.06M (+95%)
- State Street Corp+538.8K (+7%)
- Bank of America Corp+447.5K (+67%)
- JPMorgan Chase & Co+355.2K (+51%)
- Dimensional Fund Advisors+323.2K (+8%)
- AQR Capital Management−2.15M (-38%)
- Goldman Sachs Group−916.6K (-76%)
- Millennium Management−852.9K (-41%)
- Viking Global Investors−443.4K (-6%)
- Prudential Financial−290.3K (-74%)
- HANCOCK WHITNEY CORP+120.0K
- FMR LLC (Fidelity)−4.82M
- Bridgewater Associates LP−274.9K
- Blackstone Group−8.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 266 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BMRN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| 4 | Oct 1, 2026 | - | - | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Sep 14, 2026 | - | - | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BMRN SEC filings: frequently asked questions
Are BMRN insiders buying or selling?
In the last 90 days, Biomarin Pharmaceutical Inc (BMRN) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $1.5 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BMRN stock?
As of September 30, 2026, the largest Biomarin Pharmaceutical Inc (BMRN) holders among the 13F filers tracked by SignalX were BlackRock ($1.2 billion), Vanguard Capital Management LLC ($523.4 million), Vanguard Portfolio Management LLC ($502.3 million), State Street Corp ($500.4 million), Viking Global Investors ($430.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BMRN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Biomarin Pharmaceutical Inc (BMRN) reported revenue of $3.2 billion (up 12.9% from FY2024) and net income of $348.9 million. Diluted EPS was $1.80. The figures come from the XBRL data in the 10-K.
What did BMRN report in its latest 8-K?
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for period ended September 30, 2026 announced November 2, 2026.
What are the latest BMRN SEC filings?
Biomarin Pharmaceutical Inc (BMRN) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 19, 2026.
What is BMRN's SEC CIK number?
Biomarin Pharmaceutical Inc (BMRN)'s SEC Central Index Key (CIK) is 1048477. EDGAR lists every BMRN filing under that number.
Ask anything about BMRN
The research agent reads BMRN's filings, financials, insider trades and 13F holders, then answers with sources.